Ocean Biomedical(OTC) OCEA

Ocean Biomedical, Inc. is a biotechnology company that bridges the gap between groundbreaking medical research and patient solutions. Through strong affiliations with academic institutions, it licenses and develops innovations in oncology, fibrosis, and infectious diseases. The company's collaboration-driven model attracts a diverse portfolio of promising therapies, aiming to address significant unmet medical needs and improve patient outcomes.

Products and Services

Preclinical oncology therapies targeting proteins associated with tumor growth.

Fibrosis treatments focusing on molecules linked to tissue scarring.

Infectious disease solutions, including therapies and vaccines for malaria.

What Makes Ocean Biomedical, Inc. Special

Ocean Biomedical, Inc. stands out due to its strategic partnerships with research universities, enabling unique access to new scientific discoveries. This approach supports a diverse and robust pipeline, leveraging interdisciplinary expertise to efficiently bring innovative medical solutions to market.

Five Things You Need to Know

Ocean Biomedical's pipeline is primarily licensed from Brown University and Rhode Island Hospital.

The company uses a licensing and subsidiary structure to optimize value creation with its partners.

Its oncology program includes promising candidates targeting non-small cell lung cancer and glioblastoma.

Ocean Biomedical's fibrosis treatment targets idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome.

The company leverages the Whole Proteome Differential Screening platform to discover novel malaria antigens.